Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate ...
Primary Biliary Cirrhosis
Drug: Elafibranor 80mg;Drug: Placebo
Genfit
NULL
Active, not recruiting
18 Years
75 Years
All
150
Phase 3
United States;Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;South Africa;Spain;Switzerland;Turkey;United Kingdom United States;Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;South Africa;Spain;Switzerl ...